Pancreatic Cancer Research

ResearcherCross Cancer InstituteActive in the last 2 years

Michael B. Sawyer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2640-3620; OpenAlex author ID A5074419775, A5112256180. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 0, last author 5)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
2
Collaborators
13
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: 1 trial · 2010: none · 2011: none · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic canc… Co-author DOI 10.1002/ncp.70096↗
  2. Dose optimization of pancreatic enzyme replacement therapy is essential to mitigate muscle loss in patients with advanced pancreatic cancer and exocrine pancre… Last author DOI 10.1016/j.clnu.2024.06.037↗
  3. Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer. Co-author DOI 10.3390/cancers15174368↗
  4. Case report: Proton pump inhibitor drug-related problem in pancreatic cancer patient unmasks pancreatic enzyme insufficiency. Last author DOI 10.1177/10781552211038031↗
  5. Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience. Last author DOI 10.1177/10781552211038677↗
  6. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. Last author DOI 10.1016/j.clnu.2021.06.026↗
  7. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Co-author DOI 10.1093/annonc/mdu205↗
  8. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Last author DOI 10.1245/s10434-012-2686-7↗

Trials 2

  1. A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma Principal investigator NCT01065805↗
  2. An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treate… Principal investigator NCT00414570↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vera Christine Mazurak · 3 shared papers, 2023–2026 · strength 0.79
  2. Vickie Elaine Baracos · 3 shared papers, 2023–2026 · strength 0.79
  3. Pamela N. Klassen · 3 shared papers, 2023–2026 · strength 0.79
  4. Angela Chen · 2 shared papers, 2021–2022 · strength 0.35
  5. Christina Kim · 1 shared paper, 2026 · strength 0.33
  6. Jasmine Giani · 1 shared paper, 2022 · strength 0.26
  7. Susie Youn · 1 shared paper, 2021 · strength 0.15
  8. Vanessa Wylie Davis · 1 shared paper, 2013 · strength 0.05
  9. Oliver F. Bathe · 1 shared paper, 2013 · strength 0.05
  10. Edward Wang · 1 shared paper, 2014 · strength 0.04
  11. Francesco Leone · 1 shared paper, 2014 · strength 0.04
  12. Massimo Aglietta · 1 shared paper, 2014 · strength 0.04
  13. Carlo Antonio Barone · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.